MONTREAL--(BUSINESS WIRE)--Sept. 19, 2006--Caprion Pharmaceuticals Inc. announced today the completion of Phase I studies for Shigamabs(R), its therapeutic product currently in human clinical trials for the treatment of Shigatoxin-producing E. coli infections.
